UPL512070Agrochemicals
Kotak upgraded UPL to buy from reduce, though cut target price, citing specialty segment growth and backward integration strategy
By ScoutQuest · · 1 min read
- UPL forward valuation
- 13 times
Heard on business television between 12:50:51 - 12:53:51 IST.
- Kotak upgraded UPL from 'reduce' to 'buy' but cut its target price.
- Kotak cited the specialty segment 'Superform' as the next growth driver and differentiated chemistry helping UPL move into higher value segments.
- Backward integration was flagged as a key focus area to make UPL cost efficient and compete against Chinese products.
- Kotak flagged holding company discount as the key negative/overhang on the stock.
- Analyst Sharad Awasthi said at current one-year forward valuation of around 13x, UPL should be a buy, with biotech and standard business improving and inventory cycle winding down, though the demerger remains an overhang.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from UPL
Kotak Securities upgraded UPL to 'add' from 'reduce' with a fair value of 570, citing growth potential in its specialty chemicals business Superform
13 Oct 2026
Kotak Securities upgraded UPL to 'add' from 'reduce' but cut target price to 570 from 640, citing backward integration potential
13 Oct 2026
UPL up nearly 5.5% after a positive plant visit over the weekend drew favorable analyst reaction
12 Oct 2026
Source: Live TV News Channel · 13 Oct 2026
The call above is Kotak Institutional Equities's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.